Elevance Health, Inc. $ELV Stock Position Increased by Caisse Des Depots ET Consignations

Key Points

• Caisse Des Depots et Consignations increased its position in Elevance Health by 219.9% in Q4 to 6,293 shares worth $2.206 million, and institutional investors now own about 89.24% of the stock.
• Several analysts have raised price targets and ratings, leaving a consensus "Moderate Buy" with an average target of $384.58; notably, Bank of America upgraded to Buy and raised its target to $435.
• Elevance beat quarterly expectations with $12.58 EPS versus $10.74 expected and $49.49 billion in revenue versus $48.21 billion, and analysts project roughly 26.79 EPS for the current fiscal year.

Caisse Des Depots ET Consignations boosted its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 219.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,293 shares of the company's stock after purchasing an additional 4,326 shares during the quarter. Caisse Des Depots ET Consignations' holdings in Elevance Health were worth $2,206,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ELV. Physician Wealth Advisors Inc. raised its position in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company's stock worth $26,000 after buying an additional 63 shares in the last quarter. Rossby Financial LCC raised its position in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company's stock worth $28,000 after buying an additional 44 shares in the last quarter. Activest Wealth Management raised its position in shares of Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company's stock worth $27,000 after buying an additional 34 shares in the last quarter. Motco raised its position in shares of Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company's stock worth $32,000 after buying an additional 77 shares in the last quarter. Finally, ORG Partners LLC raised its position in shares of Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company's stock worth $38,000 after buying an additional 59 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Elevance Health from $332.00 to $363.00 and gave the stock a "hold" rating in a research report on Thursday, April 23rd. The Goldman Sachs Group boosted their price target on shares of Elevance Health from $350.00 to $370.00 and gave the stock a "neutral" rating in a research report on Friday, April 24th. Barclays boosted their price target on shares of Elevance Health from $393.00 to $408.00 and gave the stock an "overweight" rating in a research report on Friday, April 24th. Guggenheim boosted their price target on shares of Elevance Health from $396.00 to $399.00 and gave the stock a "buy" rating in a research report on Friday, April 24th. Finally, Bank of America upgraded shares of Elevance Health from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $405.00 to $435.00 in a report on Wednesday. Thirteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $384.58.

Elevance Health Stock Down 1.0%

NYSE ELV opened at $372.78 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company's 50 day simple moving average is $310.69 and its 200 day simple moving average is $331.90. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $424.24. The company has a market capitalization of $80.95 billion, a P/E ratio of 15.86, a PEG ratio of 2.14 and a beta of 0.66.

Elevance Health (NYSE:ELV - Get Free Report) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping analysts' consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same period in the previous year, the firm earned $11.97 EPS. The business's revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts expect that Elevance Health, Inc. will post 26.79 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health's payout ratio is presently 29.26%.

Elevance Health Company Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.